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Abstract
We have tested five distinct classes of established and experimental antimalarial drugs for their anticancer potential, using a
panel of 91 human cancer lines. Three classes of drugs: artemisinins, synthetic peroxides and DHFR (dihydrofolate
reductase) inhibitors effected potent inhibition of proliferation with IC50s in the nM- low mM range, whereas a DHODH
(dihydroorotate dehydrogenase) and a putative kinase inhibitor displayed no activity. Furthermore, significant synergies
were identified with erlotinib, imatinib, cisplatin, dasatinib and vincristine. Cluster analysis of the antimalarials based on their
differential inhibition of the various cancer lines clearly segregated the synthetic peroxides OZ277 and OZ439 from the
artemisinin cluster that included artesunate, dihydroartemisinin and artemisone, and from the DHFR inhibitors
pyrimethamine and P218 (a parasite DHFR inhibitor), emphasizing their shared mode of action. In order to further
understand the basis of the selectivity of these compounds against different cancers, microarray-based gene expression
data for 85 of the used cell lines were generated. For each compound, distinct sets of genes were identified whose
expression significantly correlated with compound sensitivity. Several of the antimalarials tested in this study have well-
established and excellent safety profiles with a plasma exposure, when conservatively used in malaria, that is well above the
IC50s that we identified in this study. Given their unique mode of action and potential for unique synergies with established
anticancer drugs, our results provide a strong basis to further explore the potential application of these compounds in
cancer in pre-clinical or and clinical settings.
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Introduction
Over the past two decades, numerous studies have identified
antitumor activities of malaria drugs. Nearly all these studies
focused on artemisinin derivatives, which are based on natural
sesquiterpene lactones with a 1,2,4-trioxane ring system. Origi-
nally isolated from Artemisia plants, this scaffold currently
represents a cornerstone of the fight against malaria [1].
Artemisinin itself and its derivatives artesunate (ART), arteether,
artemether and dihydroartemisinin (DHA) are, variously formu-
lated, used in malaria. In addition, intense activity is aimed at
exploring additional, synthetic peroxides. A considerable motiva-
tion for the interest in artemisinins in additional indications is their
excellent, well-established safety profile.
The vast majority of studies with artemisinins for use in cancer
(188 to date) involve in vitro and in vivo experiments aimed at
establishing the drug’s mode of action and potential for synergy
with established cancer drugs ([2–12]; see also the recent review
[13]). By contrast, only a few clinical studies -mostly anecdotal
findings from single cases, and one formal trial- have been
performed [[14–20]; see [21] for a recent review of clinical uses],
reporting modest improvement in patients with advanced non-
small lung cancer. In light of the vast preclinical literature on
anticancer properties of artemisinins and their excellent, well-
established safety profile it is surprising that there are not more
reports, or more widespread off-label use of artemisinins for
cancer. As was pointed out recently [21] one issue with
artemisinins is their short half-life in patients and variability in
drug exposure between patients (eg [22,23]) and over time [24,25].
These problems are no major obstacle for eliminating Plasmodium
parasites in malaria patients over a three-day cure, but may
prevent efficient inhibition of metastasis-associated angiogenesis, if
that were the principal mode of action for artemisinins’ use in
cancer. The major issue had been the lack of registration for any
indication in the US and the general lack of clinical grade material
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(produced under GMP conditions). There has been a recent step
forward here with the WHO prequalification of artesunate for
injection produced in China by Guilin in 2010, confirming that
production is at internationally recognized GMP standards, and
this product is available in Europe under special conditions.
Sigma-Tau, as part of their collaboration with the US Army, has
obtained an orphan drug designation for artesunate use against
malaria from the United States FDA, and with an FDA filing
planned for the first quarter in 2014 (Pietro Grossi, pers. comm.).
This should pave the way to the registration of an artesunate for
injection in the USA early in 2014.
In spite of extensive efforts and significant progress, the mode of
action of artemisinins in eliminating intra-erythrocytic Plasmodium
parasites, and their activity in cancer is still incompletely
understood. For use in malaria, structure-activity relationships
among analogs implicate the 1,2,4-trioxane peroxide pharmaco-
phore as critical for artemisinins’ function [26]. One potential
mechanism comes from the demonstration that interaction with
free Fe2+ or heme [27,28] _ENREF_36 triggers a chemical
cascade that generates multiple, toxic reactive oxygen species
(ROS; reviewed in [29]). Alternatively, or in parallel, artemisinins
bind to heme and interfere with Plasmodium’s critical detoxification
of heme whereby toxic hematin is polymerized into an insoluble
crystalline form of b-hematin called hemozoin, also known as
malaria pigment. Three anticancer mechanisms have been
identified for artemisinins: A few reports suggest that artemisinins
may steer the immune system from a Th2 to a Th1-dominated
anticancer response with suppression of the Treg population [8,30].
Second, many studies find that artemisinins can interfere with
angiogenesis [31–37] by repression of VEGF and Ang-1 secretion
and interfering with chorioallantoic membrane neovasculariza-
tion. However, the vast majority of publications demonstrate that
artemisinins specifically induce apoptosis in a variety of tumor cell
lines (see [13] for a review). Molecular analysis indicates that
apoptosis is induced through the intrinsic pathway (eg [12,38,39]),
involving Bcl-2, Bcl-XL, Bak/Bax, mitochondrial release of
cytochrome c, loss of mitochondrial membrane potential and
activation of caspases 9 and 23 (but not caspase 8, which mediates
the extrinsic/TNFR-related pathway). Again, activation with Fe2+
appears to play a major role: preloading cancer cells with iron or
iron-saturated holo-transferrin significantly potentiates the induc-
tion of apoptosis (eg [40–44]). The enhanced metabolic need for
iron in cancer cells is well-established, and the up-regulated
transferrin receptor is being investigated as a means to specifically
target cancer cells [45,46]. Artemisinins appear to be directly
activated by heme [47], as illustrated by the finding that
compounds that bind mitochondrial heme also show good
cytotoxicity [48]. The critical role of mitochondrial function in
mediating the cytotoxicity of artemisinin was elegantly demon-
strated in a yeast system [49]. Importantly, this mode of action is
distinct from existing anticancer drugs. Consequently, artemisinins
have a great potential to synergize with established treatments
both in vitro and in vivo (eg [40,50–52]), even more importantly,
multi-drug resistant cancers retain sensitivity towards artemisinins
[53–56].
In order to explore the potential use of antimalarials in cancer it
is important to further link their mode of action with the critical
signaling pathways that drive cancer cell proliferation. This
enables us to move beyond a simple and antiquated categorization
of cell lines predominantly by the organ from which they
originated. Linked to this, it is important to explore what the
synergies with current anti-cancer drugs will be. The primary
focus of this study was to test the semisynthetic artemisinins
artesunate and its active metabolite dihydroartemisinin, the
semisynthetic N-thiomorphilino derivative, artemisone (BAY 44-
9585 [57]) and two synthetic peroxides, OZ277 (also called
arterolane) and OZ439. As a positive control, we also tested two
anti-parasite dihydrofolate reductase inhibitors, pyrimethamine
(recently shown to induce apoptosis in melanoma cells [58]) and P-
218 [59], which were anticipated to show some activity against a
human cancer cell panel. In addition we tested the highly selective
parasite dihydroorotate dehydrogenase (DHODH) inhibitor
DSM265 [60], and MMV 390048, a highly active anti-plasmodial
compound which is a putative kinase inhibitor. Due to their high
selectivity for parasite cells, these compounds were expected to be
largely inactive. The cancer line panel comprised conventional
commercially available cell lines as well as lines derived directly
from patient-derived tumor xenografts (PDX). In order to gain
insight in these molecules’ mode of action we correlated their
potency with the cancer lines’ gene expression patterns. Finally we
discuss our findings in the light of available pharmacokinetic data
for these drug candidates and their clinical potential.
Materials and Methods
Tumor cell lines
The cell line panel comprised 68 cell lines derived from solid
tumours and 24 cell lines derived from haematological malignan-
cies [61]. Among the solid tumor cell lines, 30 were established at
Oncotest from patient-derived tumor xenografts as described
previously [61–63]. The other cell lines were either kindly
provided by the NCI (Bethesda; MD) [64], or were purchased
from ATCC (Rockville, MD), DSMZ (Braunschweig, Germany),
ECACC (Salisbury, United Kingdom), KCLB (Seoul, Korea) or
JCRB (Osaka, Japan). Authenticity of cell lines was verified at the
DSMZ by STR (short tandem repeat) analysis, a PCR based
DNA-fingerprinting methodology [65,66]. Cell lines were rou-
tinely passaged once or twice weekly and maintained in culture for
up to 20 passages. All cells were grown at 37uC in a humidified
atmosphere with 5% CO2 in RPMI 1640 medium supplemented
with 10% (v/v) fetal calf serum and 0.1 mg/mL gentamicin
(medium and all components from PAA, Cölbe, Germany).
Cell proliferation Assays
Cells were harvested from exponential phase cultures, counted
and plated in 96 well flat-bottom microtiter plates at a cell density
of 8,000–60,000 cells/well. After a 24 h recovery period to allow
the cells to resume exponential growth, 10 ml of culture medium
(six control wells/plate) or of culture medium with test
compound(s) were added. The compounds were applied in
duplicates at ten concentrations and treatment continued for four
days. Determination of a potential synergism or antagonism by the
median-effect principle of Chou-Talalay requires application of
the combined substances at a constant, equipotent ratio, mostly at
their IC50 values. Mixtures at this constant ratio were tested at ten
different dilutions in duplicate. Additionally, each compound was
also tested in monotherapy on the same plate. Both compounds
were added simultaneously to the cells. Of each test combination,
two to three independent experiments were performed.
For solid tumor derived cell lines, a modified propidium iodide
(PI) assay [67] was used to assess the anti-cancer activity of the
compounds. After the 4 four days treatment, cells were next
washed with 200 ml PBS to remove dead cells, then 200 ml of a
solution containing 7 mg/ml propidium iodide (PI) and 0.1% (v/v)
Triton X-100 was added. After an incubation period of 1–2 hours
at room temperature, fluorescence (FU) was measured using the
CytofluorH 4000 microplate reader (excitation l= 530 nm,
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emission l= 620 nm) to quantify the amount of attached viable
cells.
For hematological cancer cell lines growing in suspension, the
CellTiter-BlueH assay (#G8081, Promega) was used according to
manufacturer’s instructions. After treatment of cells, 10 ml/well
CellTiter-BlueH reagent was added. Following an incubation
period of up to four hours, fluorescence (FU) was measured by
using the EnVision Xcite multilabel reader (excitation l= 531 nm,
emission l= 615 nm).
For calculations, the mean value of duplicate/quadruplicate
(untreated control) data was used. Calculation of IC50 values was
done by 4 parameter non-linear curve fit (Oncotest Warehouse
Software). The compounds were tested in 2–4 independent
experiments and IC50 values are shown as the mean of those
experiments.
Assessment of drug-drug interaction (determination of CI
according to Chou-Talalay)
Various two-drug combinations were evaluated using the
median-effect principle proposed by Chou and Talalay [68]. This
mathematical model, previously established for enzyme-substrate
interactions, has been extended to multiple drug combinations.
The formula of the median-effect principle is fa/fu = [D/Dm]
m,
in which fa is the fraction of the cells affected, fu (1-fa) is the fraction
unaffected by the treatment, D the drug concentration, Dm the
concentration required for 50% cell growth inhibition and m the
slope of the median-effect curve (log[fa/fu] = m log D 2 m log
(Dm). The x-intercept yields log (Dm), and thus, the Dm value. The
deviation of data from the fitted median-effect equation is
represented by the linear correlation coefficient r of the median-
effect plot. Usually the experimental data from cell culture
experiments have r .0.90.
The combination index (CI) was calculated by the Chou-
Talalay equation, which takes into account both potency (Dm or
IC50) and the shape of the dose-effect curve. The general equation
for the classic isobologram (CI = 1) is given by: CI = (D)1/(Dx)1 +
(D)2(Dx)2 + (D)1(D)2/(Dx)1/(Dx)2, where (Dx)1 and (Dx)2 in the
denominators are the drug concentrations for D1 (drug 1) and D2
(drug 2) alone that gives x% inhibition, whereas (D)1 and (D)2 in
the numerators are the concentrations of drug 1 and drug 2 in
combination that also inhibited x% (i.e. isoeffective). CI,1, C = 1,
and C.1 indicate synergism, additive effect, and antagonism,
respectively. Calculations were performed with the computer
program CalcuSyn developed by Chou and Hayball [69].
Compounds
DHA was obtained from Chongqing Holley Wuling Mountain
Pharmaceutical Co. Ltd, and artesunate from Guilin Pharmaceu-
tical Co. Ltd.; artemisone, DSM265 [60], OZ277 [70],
MMV390048 [71], OZ439 [72], OZ381 [73], P218 [59] and
carbaOZ277 [74] were synthesized as previously described.
Erlotinib and imatinib were supplied by LC-Laboratories
(Woburn, MA, USA), cisplatin and vincristine by Sigma-Aldrich
(Deisenhofen, Germany) and dasatinib by SanxinChemPharma
(Shijiazhuang, China). Test compounds (antimalarials) were
diluted in DMSO to a stock concentration of 26.7 mg/ml. Stock
solutions for erlotinib, imatinib, cisplatin and dasatinib were
prepared in DMSO at a concentration of 53.3 mM and vincristine
at 67 mM.
Microarrays
RNA was extracted from cell lines using the mirVanaH kit
(Ambion) according to the manufacturer’s instructions. The RNA
concentration was adjusted to 250 ng/ml. Biotinylated cRNA was
prepared according to the standard Affymetrix protocol from
total RNA (Expression Analysis Technical Manual, 2001,
Affymetrix).
All microarray gene expression profiles were obtained using the
Affymetrix HG-U133 Plus 2.0 GeneChip arrays. Hybridization
was carried out according to standard Affymetrix protocol for 39
IVT design and the GeneChips were scanned using the Hewlett-
Packard GeneArray Scanner G2500A. All chips were assessed for
Figure 1. Molecular structures of compounds used in this study.
doi:10.1371/journal.pone.0082962.g001
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quality using the ‘‘R’’ statistical computing environment and
associated modules from Bioconductor with Percent Present cut-
off of 35%, resulting in only a single array being rejected.
The CEL files were processed using RMAExpress (v. 1.04,
Written by Ben Bolstad). The complete dataset (for 91 lines) was
submitted to the Gene Expression Omnibus (GEO, http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc = GSE51739) under ac-
cession number GSE51739. Following background adjust, quan-
tile normalization and Median Polish summarization, expression
values were exported in natural scale for further analysis.
Affymetrix probeset annotations for the HG-U133_Plus_2 micro-
array were taken from build 33 (29 Oct 2012). Using the ExcelH
CORREL (Pearson’s) function, IC50s for each cell line were
correlated with expression values, for a given compound and gene.
In addition, probabilities for significance of these correlations were
calculated using the ExcelH formula = TDIST(ABS([Correla-
tion]*SQRT([nr of observations-2])/SQRT(1-[Correlation]‘2)),
([nr of observations-2],2). In this function, ‘‘Correlation’’ refers
to correlation efficient r as calculated earlier, while ‘‘nr of
observations’’ refers to the number of cell lines tested.
In order to subdivide sets of genes associated with compound
potency into clusters with similar function, Gene Ontology
Biological Process assignments (http://www.geneontology.org/)
were taken from the Affymetrix annotation file. Frequency scoring
and data processing were performed in ExcelH. Cluster analysis
was performed using the Excel add-in Multibase 2013 package
(Numerical Dynamics, Japan), using the Ward method (Cluster
membership is assessed by calculating the total sum of squared
deviations from the mean of a cluster).
Results
Testing of antimalarials for activity against cancer cell
lines
Antimalarials representing five distinct target classes were tested
in this study: (i) the three artemisinins artesunate, dihydroartemi-
sinin (Artenimol, DHA), and artemisone (BAY 44-9585), another
semi-synthetic artemisinin derivative that presents an improved
safety profile [57,75]; (ii) synthetic ozonides OZ439 and 277,
synthetic peroxides with enhanced in vivo stability [76]; (iii)
pyrimethamine and P218, established and second-generation
DHFR (dihydrofolate reductase) inhibitors, respectively [59]; (iv)
DSM265, a potent and selective triazolopyrimidine-based inhib-
itor of the enzyme dihydroorotate dehydrogenase (DHODH)
which kills Plasmodium in vitro and in an in vivo mouse model [60];
(v) MMV390048, a 3,5-diaryl-2-aminopyridine/2-trifluoromethyl-
pyridine that is hypothesized to kill Plasmodium by inhibiting one or
more of the parasite’s kinases.
We included carbaOZ277, an inactive non-peroxide derivative
of OZ 277 and OZ 381 and OZ 277, analogs of OZ277 and
OZ439 (See Fig. 1 for their structures). As a positive control
Paclitaxel, an established cancer drug, was included.
Fig. 2 lists the potencies as IC50 (mM) for the set of solid tumors
and leukemic cell lines tested, and the origin (organs) of the lines.
There is considerable variation both between compounds and, for
a given compound, between cell lines tested. In addition to
paclitaxel, strong potencies were seen for the three artemisinins,
the two synthetic peroxides and the two DHFR inhibitors. By
contrast, the DHODH and assumed kinase inhibitors and negative
control compounds (OZ381, OZ721, carbaOZ277) lacked antitu-
mor activity in these assays. This is the first demonstration of an
anticancer activity of synthetic peroxides. While a single study has
demonstrated that pyrimethamine induces apoptosis in melanoma
cells [58], we here extend these findings to a much larger panel of
cancer types. In addition by using a second, different but related
DHFR inhibitor, the fingerprint of specific inhibition can be
defined. In some cases, lines that were relatively insensitive to
Figure 2. IC50s (in mM) of various antimalarials for a panel of
human tumor cell lines. DT, h doubling time (hours).
doi:10.1371/journal.pone.0082962.g002
Anticancer Properties of Antimalarial Drug Classes
PLOS ONE | www.plosone.org 4 December 2013 | Volume 8 | Issue 12 | e82962
paclitaxel also showed resistance to the antimalarials, especially the
hepatoma lines (e.g. HLE, SNU423, SNU739). By contrast, other
lines that responded poorly to paclitaxel showed excellent
sensitivity towards the antimalarials (e.g. gastric cancer IM9).
Effects of antimalarials on cancer cell expression profiles
by microarray analysis
In order to group the compounds tested on the basis of their
relative potencies in this cell line panel we performed a cluster
analysis, with the compound’s IC50s as input for the MultiBase
analytical package from Numerical Dynamics. As shown in Fig. 3,
this analysis most tightly clustered the two synthetic peroxides and
the two DHFR inhibitors. Surprisingly, paclitaxel clustered with
ART, DHA and Artemisone. While artemisinins and paclitaxel
each kill cancer cells by inducing apoptosis, the former
(artemisinins) are believed to do so through the intrinsic apoptotic
pathway involving caspase 3 and 29, whereas paclitaxel exploits
the caspase 8 pathway [77]. The similarity we observe here could
Figure 3. Cluster analysis for IC50s of various antimalarials. The IC50 stands for the compound concentration where half-maximal inhibition is
observed.
doi:10.1371/journal.pone.0082962.g003
Figure 4. Assessment of drug-drug interaction (determination according to Chou-Talalay); A purely additive effect results in C = 1;
lower Cl values reflect synergy (see Methods for details).
doi:10.1371/journal.pone.0082962.g004
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reflect that some of the cancer lines we have used are susceptible to
apoptosis induced by either pathway. The fact that the synthetic
peroxides cluster separately as a group, and are clearly separated
from the artemisinins is intriguing. It suggests that the synthetic
peroxides kill cancer cells by more than one mechanism in spite of
the fact that they share a characteristic peroxide pharmacophore
with the artemisinins. This also suggests that the mechanisms
whereby these human cell lines develop resistance to artemisinins
and to the synthetic peroxides could be completely different.
Since we found that the different antimalarials tested displayed
distinct characteristics potentially reflecting diverse mode of
actions we decided to further explore these compounds for
potential synergies with the established anticancer drugs erlotinib,
imatinib, cisplatin, dasatinib and vincristine. Using a subset of cell
lines, the antimalarials were tested at three different concentrations
together with a gradient of these anticancer drugs. The assessment
of drug-drug interaction was determined according to Chou-
Talalay (see Methods) and the results are displayed in Fig. 4. Both
OZ 277 and ART exercised significant synergy with vincristine (as
reflected by a low Cl value in the red-colored cells). Vincristine is
known to polymerize microtubules, resulting in mitotic arrest in
the metaphase, while earlier mitotic phases are unaffected [78]. By
contrast, artemisinins are known to arrest cell division at a much
earlier stage, namely the G1/G2 phase (eg. [56,79]). Thus, while
both type of compounds eventually induce apoptosis, it is possible
that cells that somehow escape from the G1/2 phase block are
subsequently trapped in the metaphase due to the action of
vincristine, resulting in a synergetic mode of action.
Erlotinib is an EGFR (Epidermal growth factor receptor)
inhibitor that we found synergizes with ART in five out of eight
lines tested, while dasatinib, a c-abl inhibitor, stimulated activity in
three lines. Since kinase inhibitors typically target a set of related
kinases it may be difficult to predict which lines may present the
best synergistic response.
The checkered appearance of the Table in Fig. 2 reflects the
modern view that cancers should be characterized by the
molecular mechanism(s) that allows them to escape from
proliferative controls, as opposed to a characterization by their
organ of origin. In order to gain further insight in the molecular
mechanisms that are associated with the compound’s potencies we
performed a gene expression microarray analysis of nearly every
cell line used in this panel. For each compound tested, we
subsequently correlated its inhibitory pattern throughout the cell
line panel with gene expression variation, calculating correlation
coefficients and their associated probabilities for each gene in the
array (see Methods). We thus obtained, for each compound, lists of
genes whose expression pattern correlated (positively or negatively)
with compound potencies. Examples of such correlations are
shown in Fig. 5. While expression of tollip (two probe sets) in most
cell lines was somewhat below our 500 cutoff, potency of DHA is
negatively correlated with expression of this gene (see Supplemen-
tal S1), a kinase substrate implicated in breast cancer [80]. A
Figure 5. Relationship between gene expression across the
cancer cell lines and IC50, for the indicated antimalarial and
gene (HUGO code). CREG1: cellular repressor of E1A-stimulated
genes 1, SERPINB1: serpin peptidase inhibitor, clade B (ovalbumin),
member 1, GGH: c-glutamyl, RPL7: ribosomal protein L7, LASP1: LIM and
SH3 protein 1, SRSF1: serine/arginine-rich splicing factor 1, SLC35B1:
solute carrier family 35, member B1, MRPS24: mitochondrial ribosomal
protein, TMEM147: transmembrane protein 147, TRA2B: transformer 2
beta homolog (Drosophila), RPS27A: ribosomal protein S27a, TSG101:
tumor susceptibility gene 101, RBM8A: RNA binding motif protein 8A,
LDHB: lactate dehydrogenase B, BCLAF1: BCL2-associated transcription
factor 1.
doi:10.1371/journal.pone.0082962.g005
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similar example is DUSP8, a gene whose promoter methylation
predicts clinical outcome of ovarian cancer [81] and MAP-
KAPK2, which is known to regulate invasion of bladder cancer
[82]. In order to obtain an aggregate, functional view of these
associated genes we listed, for each compound, all genes whose
expression significantly (cutoff p,0.0005) correlated with com-
pound potency (positive and negative correlations were grouped).
The corrected (Bonferroni) threshold for the 16,722 genes that we
considered (those with expression signal .500) would be at
p,3.1026; however, this type of correction has been criticized as
conservative (eg [83]) and might in our case skew the subsequent
aggregate analysis (see below), which is less sensitive to the false
discovery rate. The lists of genes associated with each compound
are provided as a Supplement (S1). Next, the functional
annotations (from the Gene Ontology Biological Process assign-
ments, eg ‘‘DNA repair’’) for the genes in each list were
catalogued, and their frequencies (top 30) were plotted in
histograms (Fig. 6), along with the number of genes for each list;
similar results were obtained using the GENECODIS package
([84], data not shown). As expected, regulatory genes involved in
signal transduction, transcription and apoptosis were prominent
but, given that different gene sets associated with the compounds,
remarkably similar; presumably, different genes associated with
the various compounds were binned in the same category, resulting
in the apparent convergence when results are displayed in this ‘‘high-
level’’ format. Previously, a similar study to ours was performed with
artesunate, but using a different cell line panel and microarray
platform [85]. Interestingly, the top-ranked ‘‘resistance’’ gene in that
study, SLC30A1, was also assigned by us as such (Data S1), and we
found that expression of this gene was only significantly associated
with ART (p = 0.0026), not the other compounds, emphasizing the
unique character of each compound that we tested. SLC30A1 is a
zinc efflux transporter; a Plasmodium orthologue exists with Swissprot
accession Q8IBU1. One possibility that explains the confirmed link
with ART resistance is that overexpression of zinc transporters
protects from apoptosis [86]. The gene is also important in
erythrocytes [87] and may affect the uptake of Fe2+ [88], which
was shown to be a critical mediator of ART toxicity [89–92].
Another published study that evaluated ART and gene expression
used the NCI60 cell line panel (from the National Institute for
Cancer [64]). This study [90] identified the transferrin receptor
(TRFC) as associated with ART resistance; in our study we also find
this gene to be significantly associated with ART, artemisone and
DHA (p = 0.01, 0.001 and 0.01, respectively) also as a ‘‘sensitivity
gene’’ (i.e., higher expression results in greater compound sensitiv-
ity). From that study, we also confirmed the association of ART
inhibition with ABC Transporter ABCB7 (p = 0.01).
Finally, a pathway analysis was performed to graphically display
relationships between sets of genes in terms of the molecular partners
they are known to interact with; using this type of analysis, separate
sets of genes may reveal that they interact with a common ‘‘target’’
set of genes. However, an analysis using the VisANT package
revealed no obvious relationships ([93,94]; data not shown). One of
the difficulties with this and similar packages (such as Ingenuity
Pathway Analysis) is that ‘‘interactions’’ are derived from disparate
observations: protein-protein interactions and enzyme-substrate
relationship from different cell types and in various contexts. These
relations are as yet incomplete and biased towards intensely studied
and abundant (protein-protein interactions) partners.
Figure 6. Predicted biological function (top 30) of genes whose
expression is associated with IC50 (p,0.0005) for the various
compounds. The histograms list biological processes that determine
whether a drug will inhibit growth.
doi:10.1371/journal.pone.0082962.g006
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Discussion
We have evaluated five distinct classes of antimalarials for their
potential use in cancer. Three of these, the artemisinins, the
synthetic peroxides and DHFR (dihydrofolate reductase) inhibitors
potently inhibited the growth of several human cancer lines. This
high success rate may appear surprising, however, parasites and
cancer cells share basic characteristics related to the metabolic
requirements associated with their high proliferation rate. The
Table 1. Human pharmacokinetics of antimalarials tested in this study.
Compound (mg) Cmax AUC Source Half-life
OZ 439 (capsule)
50 17 ng/ml 102 ng.h/ml [99]
100 34 ng/ml 249 ng.h/ml [99]
200 102 ng/ml 890 ng.h/ml [99]
400 135 ng/ml 1,130 ng.h/ml [99]
800 315 ng/ml 3,010 ng.h/ml [99] 27.9 h
1,200 701 ng/ml 6,530 ng.h/ml [99] 31.6 h
OZ 439 (dispersion)
400 566 ng/ml 5,430 ng.h/ml [99] t1/2 = 31.2 h
800 917 ng/ml 9,630 ng.h/ml [99] t1/2 = 25.2 h
1,600 1,340 ng/ml 17,500 ng.h/ml [99] t1/2 = 30.7 h
800 ,2,400 ng/ml [99]
800–1,200 ,1,600 ng/ml [99]
OZ 277
50 8 ng/ml 40 ng.h/ml (0–8 h) [101]
100 19 ng/ml 105 ng.h/ml [101]
200 41 ng/ml 239 ng.h/ml [101]
50 14 ng/ml 79 ng.h/ml (0–8 h) [101]
100 25 ng/ml 152 ng.h/ml [101]
200 68 ng/ml 408 ng.h/ml [101]
ART/DHA
120 mg iv 13,700–17,000 ng/ml 876–1,038 ng.h/ml [98] 2–3 min
120 mg iv; DHA readout 1,500–2,760 ng/ml 1,845–3,298 ng.h/ml [98] 0.49–0.87 h
200 mg po 67–119 ng/ml 67–256 ng.h/ml [98]
200 mg po, DHA readout 654 ng/ml 1,158–1,300 ng.h/ml [98]
120 mg im 884 ng/ml 999 ng.h/ml [98] 41 min
120 mg im, DHA readout 1,166 ng/ml 2,474 ng.h/ml [98] 64 min
120 mg ir 448 ng/ml 796 ng.h/ml [98] 0.95 h
120 mg ir, DHA readout 219 ng/ml 965 ng.h/ml [98] 1.2 h
40 mg DHA 39 ng/ml 98 ng.h/ml (infin.)
60 mg ART 183 ng/ml 155 ng.h/ml (infin.)
Artemisone
10 mg po 40 ng/ml 30 ng.h/ml [102] Up to 33.5 h
20 mg po 57 ng/ml 66 ng.h/ml [102]
30 mg po 51 ng/ml 72 ng.h/ml [102]
40 mg po 83 ng/ml 118 ng.h/ml [102]
80 mg po 140 ng/ml 282 ng.h/ml [102]
pyrimethamine
75 mg po 34,700–38,400 ng.h/ml [103]
50 mg/d, 3 wk 2,059 ng/ml 41,800 ng/ml *h (24 h) [100] 191 h
75 mg single dose ,800 ng/ml 106,065 ng *h/ml [104]
25 mg single dose 760 ng/ml 76,000 ng *h/ml [105] 114 h
P218
Rat 30 mg/kg 15.8 uM (,6,257 ng/ml) [59] 7.3 h
doi:10.1371/journal.pone.0082962.t001
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parasiticidal and anticancer mechanisms of artemisinins have been
extensively studied and are now well understood to be linked to an
environment rich in free or heme-bound intracellular Fe2+ and the
induction of apoptosis [13]. Nevertheless there are still uncertain-
ties over the relative importance of the direct generation of
reactive oxygen species and more indirect consequences of
artemisinins binding to mitochondrial heme and the induction of
the intrinsic apoptotic pathway. Our surprising finding that the
three artemisinins can functionally be clearly distinguished from
the synthetic peroxides, in spite of the fact that they all share a
common peroxide pharmacophore, strongly suggests that these
molecules have multiple modes of action, not all of which are
distributed equally among members of the two families. DHFR is
required for the mitochondrial thymidylate biosynthesis pathway,
a critical process in rapidly reproducing cells. While the
antiproliferative properties of these antifolates had mostly been
evaluated in rapidly proliferating T lymphocytes, their potential
use in cancer was only recently identified [58]. The present study
confirms and extends these findings: we include a novel parasite
DHFR inhibitor P218, that displays similar anticancer properties
as pyrimethamine, and the similarity of the changes in the gene
expression profiles of cell lines inhibited by the two compounds
suggests a similarity in the mode of action. One of the reasons for
developing P218 is the existing resistance observed in field isolates
of Plasmodium to pyrimethamine. The similarity in the profiles of
cancer cell lines inhibited by the two compounds, suggests that
P218 may also be considered in combination with pyrimethamine
to prevent the emergence of DHFR resistant tumor cells. We
found no significant activity for DHODH inhibitors. One
explanation for this is the stringent species specificity of these
drugs (which target the Plasmodium ortholog), since one DHODH
inhibitor, brequinar, did show (modest) efficacy in cancer [95].
The overarching pragmatic rationale for evaluating the activity of
these antimalarials against cancer tissue-derived cell lines is that
these drugs have well-established, excellent safety profiles.
Furthermore, as we have shown in this study, their unique modes
of action present opportunities for combinatorial use with
established cancer drugs. Artemisinins are known to stall mitosis
at the G1/G2 phase, while pyrimethamine results in a block at the
S-phase [58] and paclitaxel at the metaphase; possibly such
considerations constitute a firmer basis for deciding on potential
for synergy between these drugs than a focus on the upstream
pathways that these cancer cells utilize to drive proliferation.
Furthermore, at least for the time being our descriptive capabilities
(genetics and transcriptomics) have greatly outpaced our integra-
tive capacity, in other words, our ability to reduce these data into
an understanding of a cancer cell’s specificity to cause disease.
Either way, discovery of optimal combinatorial strategies remains
therefore a matter of trial and error. In other words, while our
data indicate that these compounds behave strikingly different, this
knowledge cannot yet be translated into reliable predictions of how
they should be used.
In order to assess the potential of these antimalarial compounds
for a use in cancer chemotherapy it is also important to compare
our data with their exposure in human subjects. Table 1
summarizes key pharmacokinetic properties for the active
compounds used in this study, including Cmax, AUC (Area Under
the Curve) and plasma half-life. Unfortunately these values are
typically presented as weight/ml; as a rule of thumb and for
comparison with the data in Fig. 2, 1 mg/ml corresponds to
2–3 mM (for compounds with MW 500 and 333, resp.). As the
Table shows, artemisinins generally have a short plasma half-life.
They are considered prodrugs with rapid conversion into DHA,
which has a somewhat longer half-life. Since we show that both
ART and its derivative DHA have anticancer properties, we can
predict that efficacy may be better than one would assume from
looking at exposure of either substance alone. Among the different
artemisinin derivatives, artesunate is best suited for iv administra-
tion, providing a means for achieving the highest exposure. It is
therefore presently the treatment of choice for acute malaria
[96,97] with peak exposure of 14–17 mg/ml when dosed at
120 mg iv [98], which is well above the IC50 for many of the cell
lines that we tested (Fig. 2), even though the potencies that we
found in our anticancer assays are much weaker than what is
found when testing against Plasmodium (eg in the nM range for
artesunate [75]). The short half-life of some of the compounds that
we tested may be a problem for a mode of action that would
involve inhibition of angiogenesis [21], but this is probably not a
problem for antiproliferative uses (as against Plasmodium); successful
anticancer drugs such as cisplatin and taxol also have rather short
half-lives (1.5–3.6 and 5.8 h respectively). For the synthetic
peroxides, exposure of the advanced second generation drug
candidate OZ 439 reaches 2.4 mg/ml, or 5.1 mM [99]. This
concentration brings the compound very close to the IC50s that we
found for a number of cancer lines (Fig. 2). So far, this compound
has been conservatively dosed in volunteers, commensurate with a
use in malaria patients; however, its excellent safety profile could
allow for significantly higher exposure in cancer patients. Also, in
contrast to artemisinins the compound has excellent half-life
properties, thus presenting considerable potential for clinical use.
Finally, pyrimethamine generates an exposure of 2,059 ng/ml
(,8 mM; [100]), well above the IC50 of the majority of cell lines
that we tested (Fig. 2). While the exposure in humans for P218 is
not yet known, our study suggests that this compound has the
potential to address resistance against this category of drugs both
in malaria and cancer.
In summary, we have established that three mechanistically
different antimalarials show potent in vitro activity for a variety of
cancer cell lines at concentrations that are established or reachable
in patients. We also demonstrate evidence for potential synergy
with established cancer drugs.
Given the well-established safety profile of these drugs, further
evaluation of their potential in a clinical setting is recommended.
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